Subclinical Hypothyroidism

Article Author:
Shiva Kumar Gosi
Article Editor:
Vishnu Garla
Updated:
1/30/2019 10:18:07 AM
PubMed Link:
Subclinical Hypothyroidism

Introduction

Subclinical hypothyroidism characteristically presents with elevated thyroid-stimulating hormone (TSH) and normal thyroxine (T4) levels.[1]Various studies have reported the incidence of subclinical hypothyroidism to be 3-15% depending on the population studied.[2][3] The prevalence of this disorder is bound to increase due to the increased availability of thyroid function testing. Although TSH levels vary widely in the population, intraindividual variation is minimal; this is secondary to a unique individual setpoint in the hypothalamic-pituitary axis.[4] Subclinical hypothyroidism correlates with an increased risk of fatal and non-fatal coronary artery disease (CAD) events, congestive heart failure and fatal stroke.[5][6]

Etiology

Subclinical hypothyroidism and hypothyroidism share the same etiologies. Worldwide iodine deficiency is the most common cause of hypothyroidism. However, in the United States, autoimmune thyroiditis is the most common cause of hypothyroidism. Other causes include post-surgical or post-ablative hypothyroidism, central hypothyroidism, and medication-induced hypothyroidism.[7]

Epidemiology

The prevalence of subclinical hypothyroidism varies from 3 to 15% based on the study population. Statistical research demonstrates a higher incidence of subclinical hypothyroidism in women and elderly individuals. Vanderpump et al. in the Whickham survey found 8% of women and 3% of men to have subclinical hypothyroidism.[3]The risk of subclinical hypothyroidism progression to overt hypothyroidism is 2 to 6% per year. The risk is higher in women having TSH of greater than 10 mIU/ml and positive thyroid peroxidase (TPO) antibody.[8][9]

Pathophysiology

In the USA, the most common cause of hypothyroidism is Hashimoto thyroiditis; characterized by lymphocytic infiltration, fibrosis, and atrophy of the thyroid gland. CD8 cells in the lymphocytic infiltrate are responsible for the destruction of the thyroid gland.[10]

History and Physical

Subclinical hypothyroidism is asymptomatic most of the time. However, it can present with symptoms of hypothyroidism.[7] It is essential to assess hypothyroid symptoms as it influences whether thyroid replacement therapy requires initiation. The clinical features of hypothyroidism are as follows:

  1. Integumentary: Dry skin, hair loss, loss of outer 1/3rd of eyebrows, facial puffiness.
  2. Gastrointestinal: Constipation, dysphagia, loss of appetite, weight gain, cholelithiasis
  3. Cardiovascular: Diastolic hypertension, bradycardia, pericardial effusions.
  4. Neurological: Decreased attention span, pseudodementia, mononeuropathies (most commonly carpal tunnel syndrome)
  5. Musculoskeletal: Muscular weakness, cramps, stiffness, fatigue.
  6. Reproductive: Irregular periods, decreased libido.[11]

Evaluation

The hallmark of subclinical hypothyroidism is an elevated TSH with a normal T4. However there are several non-thyroidal factors which can cause elevation of TSH, and they need to be ruled out before a diagnosis of subclinical hypothyroidism is made. Recommendations are that TSH and T4 need to be repeated at least once after 2-3 months. TPO antibodies which indicate an autoimmune etiology of hypothyroidism should be measured. They correlate with a two-fold increased risk of progression of subclinical hypothyroidism to overt hypothyroidism. The TPO antibody titers decrease with time and do not need repeating. An ultrasound would show a hypoechoic and heterogenous thyroid gland in patients with autoimmune thyroid disease. 

Since subclinical hypothyroidism has potential associations with cardiovascular disease, congestive heart failure, and cognitive decline patients should be evaluated for their risk of atherosclerotic cardiovascular disease and other risk factors.[7]

Treatment / Management

The central question in the treatment of subclinical hypothyroidism is when to initiate levothyroxine therapy. Factors which need to be taken into account to decide on levothyroxine therapy are age, elevation of TSH, associated cardiovascular risk factors, clinical symptoms of hypothyroidism and presence of thyroid peroxidase antibodies.

Both the American Thyroid Association (ATA) and American Association of Clinical Endocrinology (AACE) recommend starting levothyroxine therapy under the following scenarios:

  • TSH is >10 mIU/l or;
  • Presence of hypothyroid symptoms or;
  • Presence of cardiovascular risk factors or;
  • Positive TPO antibody.

The goal of levothyroxine therapy is to normalize TSH. The starting of levothyroxine is 1.5 mcg/kg in the absence of cardiovascular disease. In patients with cardiovascular disease, the starting dose of levothyroxine is 25 mcg and is up-titrated as needed.[11]

Differential Diagnosis

There are several non-thyroid factors which can transiently elevate TSH and lead to misdiagnosis as subclinical hypothyroidism. It is essential to distinguish between these non-thyroid causes of elevation in TSH from true subclinical hypothyroidism.

  1. Age
  2. Nonthyroidal illness
  3. Laboratory assay interference
  4. Adrenal insufficiency
  5. Chronic renal failure
  6. Medications: Amiodarone, metoclopramide, amphetamine, ritonavir, and St. Johns Wort[12]

Complications

1. Cardiovascular risk: Hypothyroidism is associated with increased vascular resistance and decreased cardiac output. Lack of triiodothyronine (T3) impairs the vasodilatory action of nitric oxide on the vasculature resulting in increased vascular resistance. Thyroid hormones have positive chronotropic by directly stimulating the sinoatrial node and positive inotropic effect by modulating myocyte-specific regulatory proteins increasing cardiac contractility. Lack of thyroid hormone results in bradycardia and decreased cardiac output.[13][14] Rodondi et al. studied 55,000 patients and found that a TSH of >10 mIU/l correlated with an increased risk of coronary artery disease events (hazard ratio of 1.86) and cardiovascular mortality (Hazard ratio of 1.58).[15] However, Gusekloo et al. showed that in elderly individuals (>85 years) higher TSH levels were associated with a reduced mortality rate.[16] Adrees et al. showed that the increased levels of cholesterol, blood pressure, homocysteine associated with subclinical hypothyroidism normalized after 18 months of levothyroxine treatment.[17]

2. Functional capacity: Subclinical hypothyroidism has been associated with decreased muscular strength and exercise capacity. Mainenti et al. randomized 23 women with subclinical hypothyroidism to receive levothyroxine or placebo. After 6 months of TSH normalization increase exercise performance was noted in the treatment group.[18]

3. Cognitive impairment: Hypothyroidism has been known to be associated with cognitive decline. Triiodothyronine plays an important role in neuronal growth, migration and myelination. However, studies have yielded conflicting results on the association of subclinical hypothyroidism and cognitive impairment. Pasqualetti et al. in their meta-analysis of 13 studies found an increased risk of cognitive decline in patients younger than 75 years with subclinical hypothyroidism.[19] In contrast, Akintola et al. in their meta-analysis of 15 studies found no increased risk of cognitive impairment with subclinical hypothyroidism.[20]

Pearls and Other Issues

  • Subclinical hypothyroidism characteristically has an elevated TSH and normal T4. While most patients are asymptomatic, some may have symptoms of hypothyroidism.
  • Subclinical hypothyroidism requires differentiation from other causes of a transient elevation of TSH (Age, medications, renal failure, non-thyroidal illness, and assay interference)
  • Subclinical hypothyroidism has potential correlations with an increased risk of cardiovascular disease, cognitive decline, and a decrease in functional capacity.
  • Treatment with levothyroxine should commence if the level of TSH is >10 mIU/l, with positive thyroid peroxidase antibody, the presence of hypothyroid symptoms, or cardiovascular risk factors.

Enhancing Healthcare Team Outcomes

A multidisciplinary team is the best approach to subclinical hypothyroidism management. The central question in the treatment of subclinical hypothyroidism is when to initiate levothyroxine therapy. Factors which need to be taken into account to decide on levothyroxine therapy are age, elevation of TSH, associated cardiovascular risk factors, clinical symptoms of hypothyroidism and presence of thyroid peroxidase antibodies.


References

[1] Cooper DS, Clinical practice. Subclinical hypothyroidism. The New England journal of medicine. 2001 Jul 26;     [PubMed PMID: 11474665]
[2] Canaris GJ,Manowitz NR,Mayor G,Ridgway EC, The Colorado thyroid disease prevalence study. Archives of internal medicine. 2000 Feb 28;     [PubMed PMID: 10695693]
[3] Vanderpump MP,Tunbridge WM,French JM,Appleton D,Bates D,Clark F,Grimley Evans J,Hasan DM,Rodgers H,Tunbridge F, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clinical endocrinology. 1995 Jul;     [PubMed PMID: 7641412]
[4] Andersen S,Pedersen KM,Bruun NH,Laurberg P, Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. The Journal of clinical endocrinology and metabolism. 2002 Mar;     [PubMed PMID: 11889165]
[5] Chaker L,Baumgartner C,den Elzen WP,Ikram MA,Blum MR,Collet TH,Bakker SJ,Dehghan A,Drechsler C,Luben RN,Hofman A,Portegies ML,Medici M,Iervasi G,Stott DJ,Ford I,Bremner A,Wanner C,Ferrucci L,Newman AB,Dullaart RP,Sgarbi JA,Ceresini G,Maciel RM,Westendorp RG,Jukema JW,Imaizumi M,Franklyn JA,Bauer DC,Walsh JP,Razvi S,Khaw KT,Cappola AR,Völzke H,Franco OH,Gussekloo J,Rodondi N,Peeters RP, Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis. The Journal of clinical endocrinology and metabolism. 2015 Jun;     [PubMed PMID: 25856213]
[6] Collet TH,Gussekloo J,Bauer DC,den Elzen WP,Cappola AR,Balmer P,Iervasi G,Åsvold BO,Sgarbi JA,Völzke H,Gencer B,Maciel RM,Molinaro S,Bremner A,Luben RN,Maisonneuve P,Cornuz J,Newman AB,Khaw KT,Westendorp RG,Franklyn JA,Vittinghoff E,Walsh JP,Rodondi N, Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of internal medicine. 2012 May 28;     [PubMed PMID: 22529182]
[7] Peeters RP, Subclinical Hypothyroidism. The New England journal of medicine. 2017 Jun 29;     [PubMed PMID: 28657873]
[8] Somwaru LL,Rariy CM,Arnold AM,Cappola AR, The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. The Journal of clinical endocrinology and metabolism. 2012 Jun;     [PubMed PMID: 22438233]
[9] Huber G,Staub JJ,Meier C,Mitrache C,Guglielmetti M,Huber P,Braverman LE, Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. The Journal of clinical endocrinology and metabolism. 2002 Jul;     [PubMed PMID: 12107228]
[10] Caturegli P,De Remigis A,Rose NR, Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmunity reviews. 2014 Apr-May;     [PubMed PMID: 24434360]
[11] Garber JR,Cobin RH,Gharib H,Hennessey JV,Klein I,Mechanick JI,Pessah-Pollack R,Singer PA,Woeber KA, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012 Nov-Dec;     [PubMed PMID: 23246686]
[12] Lamine F,De Giorgi S,Marino L,Michalaki M,Sykiotis GP, Subclinical hypothyroidism: new trials, old caveats. Hormones (Athens, Greece). 2018 Jun;     [PubMed PMID: 29858848]
[13] Sun ZQ,Ojamaa K,Coetzee WA,Artman M,Klein I, Effects of thyroid hormone on action potential and repolarizing currents in rat ventricular myocytes. American journal of physiology. Endocrinology and metabolism. 2000 Feb;     [PubMed PMID: 10662715]
[14] Klein I,Ojamaa K, Thyroid hormone and the cardiovascular system. The New England journal of medicine. 2001 Feb 15;     [PubMed PMID: 11172193]
[15] Rodondi N,den Elzen WP,Bauer DC,Cappola AR,Razvi S,Walsh JP,Asvold BO,Iervasi G,Imaizumi M,Collet TH,Bremner A,Maisonneuve P,Sgarbi JA,Khaw KT,Vanderpump MP,Newman AB,Cornuz J,Franklyn JA,Westendorp RG,Vittinghoff E,Gussekloo J, Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010 Sep 22;     [PubMed PMID: 20858880]
[16] Gussekloo J,van Exel E,de Craen AJ,Meinders AE,Frölich M,Westendorp RG, Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004 Dec 1;     [PubMed PMID: 15572717]
[17] Adrees M,Gibney J,El-Saeity N,Boran G, Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. Clinical endocrinology. 2009 Aug;     [PubMed PMID: 19094068]
[18] Mainenti MR,Vigário PS,Teixeira PF,Maia MD,Oliveira FP,Vaisman M, Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. Journal of endocrinological investigation. 2009 May;     [PubMed PMID: 19468264]
[19] Pasqualetti G,Pagano G,Rengo G,Ferrara N,Monzani F, Subclinical Hypothyroidism and Cognitive Impairment: Systematic Review and Meta-Analysis. The Journal of clinical endocrinology and metabolism. 2015 Nov;     [PubMed PMID: 26305618]
[20] Akintola AA,Jansen SW,van Bodegom D,van der Grond J,Westendorp RG,de Craen AJ,van Heemst D, Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis. Frontiers in aging neuroscience. 2015;     [PubMed PMID: 26321946]